Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Simulation of oral glucose tolerance tests and the corresponding isoglycemic intravenous glucose infusion studies for calculation of the incretin effect.

Kim M, Oh TJ, Lee JC, Choi K, Kim MY, Kim HC, Cho YM, Kim S.

J Korean Med Sci. 2014 Mar;29(3):378-85. doi: 10.3346/jkms.2014.29.3.378. Epub 2014 Feb 27.

2.

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes.

Mari A, Bagger JI, Ferrannini E, Holst JJ, Knop FK, Vilsbøll T.

PLoS One. 2013 Sep 3;8(9):e73154. doi: 10.1371/journal.pone.0073154. eCollection 2013.

3.

Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.

Tura A, Bagger JI, Ferrannini E, Holst JJ, Knop FK, Vilsbøll T, Mari A.

Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1123-1129. doi: 10.1016/j.numecd.2017.10.006. Epub 2017 Oct 13.

PMID:
29162361
4.

A Computational Method to Determine Glucose Infusion Rates for Isoglycemic Intravenous Glucose Infusion Study.

Choi K, Lee JC, Oh TJ, Kim M, Kim HC, Cho YM, Kim S.

IEEE J Biomed Health Inform. 2016 Jan;20(1):4-10. doi: 10.1109/JBHI.2015.2465156. Epub 2015 Aug 5.

PMID:
26259207
5.

Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

Hansen KB, Vilsbøll T, Bagger JI, Holst JJ, Knop FK.

J Clin Endocrinol Metab. 2010 Jul;95(7):3309-17. doi: 10.1210/jc.2010-0119. Epub 2010 Apr 21.

PMID:
20410219
6.

Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion.

Lund A, Bagger JI, Christensen M, Grøndahl M, van Hall G, Holst JJ, Vilsbøll T, Knop FK.

J Clin Endocrinol Metab. 2016 Nov;101(11):4377-4384. Epub 2016 Aug 17.

PMID:
27533305
7.

The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes.

Oh TJ, Kim MY, Shin JY, Lee JC, Kim S, Park KS, Cho YM.

Clin Endocrinol (Oxf). 2014 Feb;80(2):221-7. doi: 10.1111/cen.12167. Epub 2013 May 20.

PMID:
23405851
8.

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T, Madsbad S.

Diabetes Obes Metab. 2012 Jun;14(6):500-10. doi: 10.1111/j.1463-1326.2011.01549.x. Epub 2012 Jan 17.

PMID:
22171657
9.

The incretin effect in critically ill patients: a case-control study.

Nielsen ST, Janum S, Krogh-Madsen R, Solomon TP, Møller K.

Crit Care. 2015 Nov 16;19:402. doi: 10.1186/s13054-015-1118-z.

10.

Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects.

Westberg-Rasmussen S, Starup-Linde J, Hermansen K, Holst JJ, Hartmann B, Vestergaard P, Gregersen S.

Bone. 2017 Apr;97:261-266. doi: 10.1016/j.bone.2017.01.027. Epub 2017 Jan 23.

PMID:
28126633
11.

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.

Lund A, Vilsbøll T, Bagger JI, Holst JJ, Knop FK.

Am J Physiol Endocrinol Metab. 2011 Jun;300(6):E1038-46. doi: 10.1152/ajpendo.00665.2010. Epub 2011 Mar 8.

PMID:
21386059
12.

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes.

Hare KJ, Vilsbøll T, Holst JJ, Knop FK.

Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E832-7. doi: 10.1152/ajpendo.00700.2009. Epub 2010 Jan 26.

PMID:
20103744
13.

TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.

Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B, Polonsky KS.

Diabetes. 2010 Feb;59(2):479-85. doi: 10.2337/db09-1169. Epub 2009 Nov 23.

14.

Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test.

Salehi M, Aulinger B, D'Alessio DA.

Diabetes. 2012 Nov;61(11):2728-33. doi: 10.2337/db11-1825. Epub 2012 Jun 25.

15.

Downregulation of Insulin Sensitivity After Oral Glucose Administration: Evidence for the Anti-Incretin Effect.

Salinari S, Mingrone G, Bertuzzi A, Previti E, Capristo E, Rubino F.

Diabetes. 2017 Nov;66(11):2756-2763. doi: 10.2337/db17-0234. Epub 2017 Aug 29.

PMID:
28851712
16.

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose.

Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA.

Diabetes. 2014 Feb;63(2):663-74. doi: 10.2337/db13-0805. Epub 2013 Nov 1.

17.

The effect of 8 days of strict bed rest on the incretin effect in healthy volunteers.

Nielsen ST, Harder-Lauridsen NM, Benatti FB, Wedell-Neergaard AS, Lyngbæk MP, Møller K, Pedersen BK, Krogh-Madsen R.

J Appl Physiol (1985). 2016 Mar 15;120(6):608-14. doi: 10.1152/japplphysiol.00821.2015. Epub 2015 Dec 17.

PMID:
26679616
18.

Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance.

Muscelli E, Mari A, Natali A, Astiarraga BD, Camastra S, Frascerra S, Holst JJ, Ferrannini E.

Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1144-50. Epub 2006 Feb 14.

PMID:
16478775
20.

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W.

J Clin Endocrinol Metab. 1986 Aug;63(2):492-8.

PMID:
3522621

Supplemental Content

Support Center